Oliner, Jonathan D.

Amplification of a gene encoding a p53-associated protein in human sarcomas

Oliner, J. D., Kinzler, K. W., Meltzer, P. S., George, D. L., & Vogelstein, B. (1992) · Nature

Cancer-related Molecular PathwaysSarcoma Diagnosis and Treatment

Cited by 1,949

REDD1, a Developmentally Regulated Transcriptional Target of p63 and p53, Links p63 to Regulation of Reactive Oxygen Species

Ellisen, L. W., Ramsayer, K. D., Johannessen, C. M., Yang, A., Beppu, H., Minda, K., Oliner, J. D., McKeon, F., & Haber, D. A. (2002) · Molecular Cell

Cancer-related Molecular PathwaysRedox biology and oxidative stress

Cited by 474

Discovery of AMG 232, a Potent, Selective, and Orally Bioavailable MDM2–p53 Inhibitor in Clinical Development

Sun, D., Li, Z., Rew, Y., Gribble, M., Bartberger, M. D., Beck, H. P., Canon, J., Chen, A., Chen, X., Chow, D., et al. (2014) · Journal of Medicinal Chemistry

Cancer-related Molecular PathwaysHeterocyclic Compound Synthesis and Bioactivity

Cited by 290

The Role of MDM2 Amplification and Overexpression in Tumorigenesis

Oliner, J. D., Saiki, A. Y., & Caenepeel, S. (2016) · Cold Spring Harbor Perspectives in Medicine

Cancer-related Molecular PathwaysCancer Mechanisms and Therapy

Cited by 246

The MDM2 inhibitor AMG 232 demonstrates robust antitumor efficacy and potentiates the activity of p53-inducing cytotoxic agents

Canon, J., Osgood, T., Olson, S. H., Saiki, A. Y., Robertson, R., Yu, D., Eksterowicz, J., Ye, Q., Jin, L., Chen, A., et al. (2015) · Molecular Cancer Therapeutics

Cancer-related Molecular PathwaysPI3K/AKT/mTOR signaling in cancer

Cited by 152

Rational Design and Binding Mode Duality of MDM2–p53 Inhibitors

Gonzalez-Lopez de Turiso, F., Sun, D., Rew, Y., Bartberger, M. D., Beck, H. P., Canon, J., Chen, A., Chow, D., Correll, T. L., Huang, X., et al. (2013) · Journal of Medicinal Chemistry

Cancer-related Molecular PathwaysHeterocyclic Compound Synthesis and Bioactivity

Cited by 82

MDM2 antagonists synergize broadly and robustly with compounds targeting fundamental oncogenic signaling pathways

Saiki, A. Y., Caenepeel, S., Yu, D., Lofgren, J. A., Osgood, T., Robertson, R., Canon, J., Su, C., Jones, A., Zhao, X., et al. (2014) · Oncotarget

Cancer-related Molecular PathwaysPI3K/AKT/mTOR signaling in cancer

Cited by 55